- September 20 - 22, 2022
PURPOSE OF PUBLIC WORKSHOP
The purpose of the public symposium is to discuss scientific topics related to the regulation of biologics and highlight science conducted at CBER by showcasing how scientific research informs regulatory decision making, and to provide a forum for developing collaborations within FDA and with external organizations. The symposium will include presentations by experts from academic institutions, government agencies and research institutions.
Topics for Discussion
The public symposium will include presentations on the following topics: (1) advanced manufacturing and analytics; (2) advances in computational science supporting biologics’ evaluation; (3) biomarker discovery; (4) immune responses to vaccination; (5) genome therapy including gene editing; and (6) emerging and re-emerging diseases.
Persons interested in attending this public symposium must register online at https://www.eventbrite.com/e/2022-cber-science-symposium-tickets-394637380027. This public symposium will be held virtually only. Webcast information/link will be provided upon completion of registration.
If you need special accommodations due to a disability, please contact Loni Warren Henderson or Irene Carroll no later than September 6, 2022 at CBERPublicEvents@fda.hhs.gov (subject line: 2022 CBER Science Symposium).
FOR FURTHER INFORMATION CONTACT:
Loni Warren Henderson or Irene Carroll, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 1118, Silver Spring, MD 20993, 240-402-8010, CBERPublicEvents@fda.hhs.gov (subject line: 2022 CBER Science Symposium).